Navigation Links
Coronary Artery Disease ARISE Trial Showed AGI-1067 Did Not Meet,Primary Endpoint

LONDON, March 19, 2007-AstraZeneca today announced that its collaboration partner AtheroGenics, Inc. (Nasdaq: AGIX) revealed first results from the ARISE (Aggressive Reduction of Inflammation Stops Events) phase III clinical outcomes trial which studied AGI-1067, an investigational anti-atherosclerotic agent with antioxidant and anti-inflammatory effects, in patients with coronary artery disease (CAD).
The ARISE trial did not meet its primary endpoint of a statistically significant relative risk reduction in a composite cardiovascular endpoint of CV death, resuscitated cardiac arrest, non-fatal myocardial infarction, non-fatal stroke, use of coronary revascularisation and for angina pectoris with objective evidence of ischemia.

AstraZeneca and AtheroGenics will now work together to fully analyse the full data set for AGI-1067, including these first results. After completion of the final analysis, under the terms of the licence and collaboration agreement AstraZeneca has a 45-day period in which to decide whether or not to continue with the collaboration.

-Ends-
19 March 2007

Media enquiries:
Patricia O’Connor, Tel: +46 708 46 76 33
Edel McCaffrey, Tel: +44 (0) 207 304 5034
Steve Brown, Tel: +44 (0) 207 304 5033

Investor Relations:
Mina Blair, Tel: +44 (0) 207 304 5084
Jonathan Hunt, Tel: +44 (0) 207 304 5087
Jörgen Winroth, Tel: +1 (212) 579 0506
Ed Seage, Tel: +1 302 886 4065
Notes To Editors
The ARISE study
ARISE was a double-blind, randomised, placebo controlled study which involved more than 6,000 patients with coronary artery disease from over 250 centres in Canada, South Africa, the UK and the US. The study was designed to evaluate the additional benefits of adding AGI-1067 to current standard of care therapies, on several outcomes due to coronary vascular events such as death, heart attack, str oke, revascularisation and hospital admission for unstable angina.

AstraZeneca
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of $26.47 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4 Good Index.

AtheroGenics
AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including heart disease (atherosclerosis), rheumatoid arthritis and asthma. In addition to AGI-1067, the Company has another clinical-stage development programme studying AGI-1096, a novel, oral agent in Phase I that is being developed for the prevention of organ transplant rejection in collaboration with Astellas. AtheroGenics also has preclinical programmes in rheumatoid arthritis and asthma utilizing its proprietary vascular protectant® technology. For more information about AtheroGenics, please visit http://www.atherogenics.com.



'"/>




Related medicine technology :

1. New Point-of-Care Methods to Measure Coronary and Cerebrovascular Risk
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
5. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
6. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
9. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
10. SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems
11. Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 2016   TraceLink Inc ., the World,s ... Life Sciences supply chain and eliminating counterfeit prescription ... Tjoapack has selected TraceLink,s serialization solutions to help ... the rapidly approaching serialization deadlines for the U.S. ... and the EU Falsified Medicines Directive (FMD) in ...
(Date:12/7/2016)...  Varian Medical Systems (NYSE: VAR ) ... to separate its Imaging Components business.  The separation is ... Varian stockholders of common stock in Varex Imaging Corporation, ... Imaging Components business.  As part of the separation, which ... of January 2017, Varian will receive an approximate $200 ...
(Date:12/7/2016)... , Dec. 7, 2016  Organovo Holdings, ... three-dimensional biology company focused on delivering scientific and ... announced that Chairman and Chief Executive Officer ... VirtualInvestorConferences.com on Wednesday, December 14, 2016 at 1:00 ... who are not yet familiar with the Company, ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Kenall Manufacturing, a leader in sealed healthcare ... The MPCNGX is a multi-function, sealed, LED luminaire that meets the needs of everyone ... when it’s needed. , A 2’ x 4’ model features four modes: ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... a women growing up with a schizophrenic mother in a unique, personal perspective ... who specializes in treating trauma and addictive disorders at her private psychotherapy practice. ...
(Date:12/7/2016)... Valley, CA (PRWEB) , ... December 07, 2016 , ... ... be used in several ways to restore a more youthful appearance to the face. ... now offer Sculptra, along with a variety of other treatments, to rejuvenate and renew ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... When it came time to blow out ... Just 40 minutes later, the Pediatric Heart Transplant team at Joe DiMaggio Children’s ... the Weston teen the hospital’s 30th heart transplant recipient. , “He was playing at ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... planning services to families and business owners in the greater Dallas metropolitan area, ... the Dallas Fallen Officer Foundation. , Established in 2009 by active police professionals ...
Breaking Medicine News(10 mins):